MedicX Fund
BUYInvesting in healthcare properties in the UK, with all its rents government-backed, MedicX Fund shares now yield a base rate-busting 9.4%.
The closed-ended Guernsey-based fund, which raised £80m at IPO in November 2006 and has secured £100m of debt, owns 45 NHS doctors’ surgeries and primary health trusts around the UK, having added seven during the year to September. The net asset value of the properties at the year-end has been independently valued at 70.3p per share, down from 96.9p a year before, though the discounted cash flow net asset value has only fallen from 109.9p to 107.3p.
With properties unlikely to have changed hands much, the fall in value – which is equivalent to a 13% decline in the value of its sites – seems a rough estimation, but is anyway less than half the 30% fall of the benchmark of the IPD all-property index. Also, with tenants being reliable and stable – no voids on its books and rents being revised upwards every three years – it looks excessive.
The fund presently enjoys a rent-roll of £9.6m, up 4.6% over the year, and its cash yield of 5.8% compares well with the 30-year rate of 5% under which it secured its debt. The board intends to pay a final dividend of 2.6p, for an annual dividend of 5.2p.
Chairman Keith Maddin, who is one of the two investment advisers to the fund, does not plan to free up much, if any, of his current £24m cash resource, preferring to raise funds in the new year to take advantage of a claimed £85m pipeline.
AIM has numerous similarly sized funds of this ilk, tapping this solid niche. MedicX looks as good as any and, like many others, deserves a higher rating. Buy.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £44.19m
PE Forecast: n/a
Share price: 55.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
